Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

161.66B

Market cap161.66B

Price-Earnings ratio

17.72

Price-Earnings ratio17.72

Dividend yield

2.47%

Dividend yield2.47%

Average volume

6.20M

Average volume6.20M

High today

$130.87

High today$130.87

Low today

$128.88

Low today$128.88

Open price

$129.94

Open price$129.94

Volume

6.53M

Volume6.53M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$108.46

52 Week low$108.46

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $130.02. The company's market cap stands at 161.66B, with a P/E ratio of 17.72 and a dividend yield of 2.47%.

As of 2026-08-02, Gilead Sciences(GILD) stock has fluctuated between $128.88 and $130.87. The current price stands at $130.02, placing the stock +0.9% above today's low and -0.6% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 6.53M, against a daily average of 6.2M.

During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.

GILD News

Business Insider 1d

The HIV shot that could change medicine is facing its biggest test: Getting to patients - Business Insider

...

TipRanks 3d

Gilead’s Twice-Yearly HIV Strategy: What the New Phase 3 Study Means for Investors

Gilead Sciences (GILD) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confide...

Nasdaq 3d

Is Most-Watched Stock Gilead Sciences, Inc. Worth Betting on Now?

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the st...

Analyst ratings

79%

of 29 ratings

Buy

79.3%

Hold

20.7%

Sell

More GILD News

Simply Wall St 4d

Is Gilead Sciences Overvalued Following Its Trodelvy Europe Expansion Win?

Gilead Sciences (GILD) is in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use backed the use of Trodelvy plus Keytruda...

Simply Wall St 6d

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

Healthcare investors are watching AstraZeneca closely after fresh comments about operating at Chinese speed, reaffirming a 2030 sales goal of $80b and reporting...

Simply Wall St 6d

Gilead Wins Key Europe Backing For Trodelvy In Triple Negative Breast Cancer

The European Medicines Agency’s CHMP has issued a positive opinion for Trodelvy plus Keytruda in first line treatment of PD-L1 positive metastatic triple negati...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.